@article {Cantoni2021.05.24.21257729, author = {Diego Cantoni and Martin Mayora-Neto and Angalee Nadesalingham and David A. Wells and George W. Carnell and Luis Ohlendorf and Matteo Ferrari and Phil Palmer and Andrew Chan and Peter Smith and Emma M. Bentley and Sebastian Einhauser and Ralf Wagner and Mark Page and Gianmarco Raddi and Helen Baxendale and Jonathan Heeney and Nigel Temperton and HICC Consortium}, title = {Standardised, quantitative neutralisation responses to SARS-CoV-2 Variants of Concern by convalescent anti-sera from first wave infections of UK Health Care Workers and Patients}, elocation-id = {2021.05.24.21257729}, year = {2021}, doi = {10.1101/2021.05.24.21257729}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {One of the defining criteria of Variants of Concern (VOC) is their ability to evade pre-existing immunity, increased transmissibility, morbidity and/or mortality. Here we examine the capacity of convalescent serum, from a well defined cohort of healthcare workers (HCW) and Patients infected during the first wave from a national critical care centre in the UK, to neutralise B.1.1.298 variant and three VOCs; B.1.1.7, B.1.351 and P.1. Furthermore, to enable lab to lab, country to country comparisons we utilised the World Health Organisation (WHO) International Standard for anti-SARS-CoV-2 Immunoglobulin to report neutralisation findings in International Units. These findings demonstrate a significant reduction in the ability of first wave convalescent plasma to neutralise the VOCs. In addition, Patients and HCWs with more severe COVID-19 were found to have higher antibody titres and to neutralise the VOCs more effectively than individuals with milder symptoms. Widespread use of the WHO International Standard by laboratories in different countries will allow for cross-laboratory comparisons, to benchmark and to establish thresholds of protection against SARS-CoV-2 and levels of immunity in different settings and countries.Competing Interest StatementThe authors have declared no competing interest.Clinical Trial96194 12/WA/0148. Amendment 5Funding StatementThis study was undertaken by the Humoral Immune Correlates to COVID-19 (HICC) consortium, funded by the UKRI and NIHR; grant number G107217 (COV0170 - HICC: Humoral Immune Correlates for COVID19). RW and SE received funding from the StMWK (ForCOVID, Bavaria, Germany)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study approved by Research Ethics Committee Wales, IRAS: 96194 12/WA/0148. Amendment 5All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw data will made available upon request.}, URL = {https://www.medrxiv.org/content/early/2021/05/26/2021.05.24.21257729}, eprint = {https://www.medrxiv.org/content/early/2021/05/26/2021.05.24.21257729.full.pdf}, journal = {medRxiv} }